SK-HEP-1 Xenograft Model Service for Liver Cancer

The SK-HEP-1 cell line provides a highly invasive and robust in vivo platform for investigating the metastatic potential and therapeutic response of liver-derived malignancies. As a specialized pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision SK-HEP-1 Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your liver cancer drug discovery and development pipeline.

Overview of SK-HEP-1 Xenograft Model for Liver Cancer

The SK-HEP-1 xenograft model is an established in vivo translational system widely utilized in oncology research for the study of invasive liver carcinoma. By transplanting human SK-HEP-1 cells into immunodeficient rodent hosts, this model effectively reproduces aggressive tumor growth, local tissue invasion, and high metastatic propensity, which are characteristic features of advanced liver malignancies.

Biologically, the SK-HEP-1 model is highly valued for its mesenchymal-like phenotype and high migratory capacity, making it an excellent system for studying the molecular drivers of tumor progression and metastasis. This model retains essential phenotypic features of invasive carcinoma, including high proliferative rates and responsiveness to diverse pharmacological interventions. Consequently, the SK-HEP-1 model is extensively deployed in pre-clinical screening programs to assess the anti-tumor and anti-metastatic potency of novel small-molecule inhibitors, targeted biological therapies, and combination treatment regimens in a physiologically relevant in vivo setting.

Fig 1. Spontaneous metastatic xenograft model in NSG mice via injection of SK-Hep-1 and SK-Hep-1_Luc cells. (Kwon HJ, et al., 2024)

Cell Line Information: SK-HEP-1

The SK-HEP-1 cell line is derived from human adenocarcinoma of the liver. These cells exhibit rapid, invasive growth characteristics in vitro, making them a preferred choice for studying aggressive tumor behavior and therapeutic efficacy in pre-clinical models.

Our Services

Workflow of SK-HEP-1 Xenograft Model Construction

• Cell Culture & Quality Control: Human SK-HEP-1 cells are expanded in vitro using certified nutrient media under optimized physiological conditions. STR authentication and mycoplasma screening are performed prior to inoculation to ensure absolute genetic integrity and purity.
• Host Selection & Preparation: Immunodeficient rodent models are utilized for tumor engraftment, with all animals maintained in a controlled, pathogen-free environment to ensure physiological stability and consistency throughout the study.
• Precision Inoculation: A calibrated suspension of high-viability SK-HEP-1 cells is prepared, often supplemented with an extracellular matrix (e.g., Matrigel) to optimize take efficiency. Cells are inoculated in vivo via subcutaneous injection into the host flank to facilitate the development of a measurable, solid tumor.
• Longitudinal Monitoring: Tumor size is measured systematically using digital calipers to monitor volume progression. Animal health, activity, and body weight are recorded periodically to document systemic tolerance and clinical status.
• Randomization & Treatment: Once solid tumors reach a predefined, statistically significant volume, animals are randomized into matched cohorts to ensure baseline parity before the initiation of customized therapeutic dosing regimens.

Fig 2. SK-HEP-1 Xenograft Model Construction Workflow

Case Study - SK-HEP-1 Xenograft Model Development

A pre-clinical validation study was conducted using the SK-HEP-1 xenograft model to evaluate the therapeutic efficacy of a novel anti-invasive agent designed for liver carcinoma. Following the successful subcutaneous inoculation of SK-HEP-1 cells into immunodeficient mice, the host animals developed firm, rapidly expanding solid tumors. The treatment group demonstrated a clear, statistically significant inhibition of tumor growth compared to the vehicle-treated control group, confirming the model's high sensitivity and predictive reliability for screening novel liver cancer interventions.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing diverse solid tumor lineages, providing highly reproducible in vivo translational platforms for liver cancer research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive tumor growth metrics and statistical validations.

Contact us

Accelerating your liver cancer drug pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our SK-HEP-1 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.